Utilisation and off-label prescriptions of respiratory drugs in children

Sven Schmiedl, Rainald Fischer, Luisa Ibáñez, Joan Fortuny, Olaf H. Klungel, Robert Reynolds, Roman Gerlach, Martin Tauscher, Petra Thürmann, Joerg Hasford, Marietta Rottenkolber

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

15 Citacions (Web of Science)

Resum

Respiratory drugs are widely used in children to treat labeled and non-labeled indications but only some data are available quantifying comprehensively off-label usage. Thus, we aim to analyse drug utilisation and off-label prescribing of respiratory drugs focusing on age- and indication-related off-label use. Patients aged ≤18 years documented in the Bavarian Association of Statutory Health Insurance Physicians database (approx. 2 million children) between 2004 and 2008 were included in our study. Annual period prevalence rates (PPRs) per 10,000 children and the proportion of age- and indication-related off-label prescriptions were calculated and stratified by age and gender. Within the study period, highest PPRs were found for the fixed combination of clenbuterol/ambroxol (between 374-575 per 10,000 children) and the inhaled short acting beta-2-agonist salbutamol (between 378-527 per 10,000 children). Highest relative PPR increase was found for oral salbutamol (approx. 39-fold) whereas the most distinct decrease was found for oral long-acting beta-2-agonist clenbuterol (-97%). Compound classes most frequently involved in off-label prescribing were inhaled bronchodilative compounds (91,402; 37.3%) and oral beta-2-agonists (26,850; 22.5%). The highest absolute number of off-label prescriptions were found for inhaled salbutamol (n = 67,084; 42.0%) and oral clenbuterol/ambroxol (fixed combination, n = 18,897; 20.7%). Off-label prescribing due to indication was of much greater relevance than age-related off-label use. Most frequently, bronchodilative compounds were used off-label to treat respiratory tract infections. Highest off-label prescription rates were found in the youngest patients without relevant gender-related differences. Off-label prescribing of respiratory drugs is common especially in young children. Bronchodilative drugs were most frequently used off-label for treating acute bronchitis or upper respiratory tract infections underlining the essential need for a more rational prescribing in this area. © 2014 Schmiedl et al.
Idioma originalAnglès
RevistaPLoS ONE
Volum9
Número9
DOIs
Estat de la publicacióPublicada - 1 de gen. 2014

Fingerprint

Navegar pels temes de recerca de 'Utilisation and off-label prescriptions of respiratory drugs in children'. Junts formen un fingerprint únic.

Com citar-ho